A clinical study to assess the effects of Homoeopathic medicines in patients with non alcoholic fatty liver disease

Efficacy Of Individualized Homoeopathic Medicines In The Management Of Non Alcoholic Fatty Liver Disease: A Prospective Randomized Single Blind Placebo Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067829

Enrollment

354

Registered

2024-05-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Individualized Homoeopathic Medicines with Life style modification: Individualized Homoeopathic Medicines will be procured from a GMP certified company Potency Potency will be selec

Eligibility

Inclusion criteria

Inclusion criteria: Individuals with Grade I to III NAFLD established by Ultrasonography and or ALT enzymes level more than 30 IU per mL in males and more than 19 IU per mL in females Clinically diagnosed cases of Fatty Liver Patients willing to give consent either

Exclusion criteria

Exclusion criteria: Pregnant females and lactating mothers will be excluded Individuals not providing written informed consent for the study Patient with existing from liver diseases like Alcoholic Fatty Liver Grade IV Non Alcoholic fatty Liver disease viral hepatitis Autoimmune liver diseases hepatocellular carcinoma Patient with Uncontrolled Diabetes Uncontrolled Hypertension renal or cardiac disease stroke or any other serious systemic illness Patient on any other medication Patient with medical emergencies

Design outcomes

Primary

Measure	Time frame
Significant changes in the scores of Chronic Liver Disease Questionnaire for NAFLD/NASH(CLDQ NAFLD/NASH )Timepoint: At Baseline 4th month 8th month 12th month	—

Secondary

Measure	Time frame
Serum ALT levelTimepoint: At Baseline 4th month 8th month 12th month;Significant changes in BARD ScoreTimepoint: At Baseline 4th month 8th month 12th month	—

Countries

India

Contacts

Public ContactDrRajesh Kumar Verma

Pt JLN State Homoeopathic Medical College and Hospital

pjlnrhmc@gmail.com9918877844

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026